{"entity":{"id":"strive-grail","kind":"trial","name":"STRIVE (GRAIL breast screening cohort)","aka":["STRIVE","GRAIL-002"],"tldr":"A cohort of about 100,000 women having mammograms whose blood GRAIL stored to check its multi-cancer test against the cancers that appeared over the next year.","summary":"STRIVE (NCT03085888) is an observational study sponsored by GRAIL, Inc. Its registry purpose is to evaluate the pre-specified GRAIL test for invasive cancers, including blood cancers, diagnosed within one year of the first blood draw, and to refine the classifier and its cut-offs.\n\nThe registry record, read on 29 October 2026, gives its status as completed, with 99,481 participants enrolled, a start on 28 February 2017 and primary completion on 30 June 2022.","status":"completed","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT03085888","url":"https://clinicaltrials.gov/study/NCT03085888"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":["galleri"],"companies":["grail"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03085888","phase":"observational","setting":"Women having screening mammography in the United States, giving blood at the time of the mammogram so a cell-free DNA test could be evaluated against cancers diagnosed in the following year","sponsor":"GRAIL, Inc.","started":"2017-02-28","startedType":"actual","enrolled":99481,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/strive-grail/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"company":[{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/"}],"paper":[{"id":"paper-liu-ccga2-methylation-ann-oncol-2020","kind":"paper","name":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","route":"/key-papers/paper-liu-ccga2-methylation-ann-oncol-2020/"}]}}